Hyperthyroidism Complicated with Diabetes Mellitus Under the Health Promotion Model: Changes in Thyroid Hormones, Glucose-Lipid Metabolism, and Inflammatory Markers
Abstract
Objective: To investigate the effects of a Health Promotion Model (HPM)-based comprehensive intervention on thyroid hormones, glucose-lipid metabolism, and inflammatory markers in patients with hyperthyroidism (HT) complicated by diabetes mellitus (DM), and to elucidate the potential mechanisms underlying these effects.
Methods: A total of 142 patients diagnosed with HT and DM between January 2024 and January 2025 were enrolled. Participants were divided into two groups: the HPM group (n=64), which received a structured HPM-based intervention, and the conventional group (n=78), which underwent standard management. Laboratory assessments were conducted before and after the intervention to evaluate thyroid hormones (FT3, FT4, TSH), glucose-lipid metabolism parameters (fasting plasma glucose [FPG], glycated hemoglobin [HbA1c], total cholesterol [TC], triglycerides [TG]), inflammatory markers (high-sensitivity C-reactive protein [hs-CRP], interleukin-1β/6 [IL-1β/IL-6]), and bone metabolism indicators (osteocalcin [BGP], alkaline phosphatase [ALP], calcitonin [CT]). Data were analyzed using SPSS 24.0.
Results: Compared to the conventional group, the HPM group exhibited significantly greater improvements in thyroid function, with more pronounced reductions in FT3 and FT4 (P<0.05) and a greater increase in TSH (P<0.05). Regarding glucose-lipid metabolism, significantly larger decreases in FPG, HbA1c, TC, and TG were identified in the HPM group (P<0.05). Among inflammatory markers, the HPM group showed significant reductions in hs-CRP, IL-1β, IL-6, MIP-1α, and MMP-9 (P<0.05), whereas the conventional group only exhibited improvements in hs-CRP and IL-1β (P<0.05). No significant intergroup differences were observed in bone metabolism parameters (BGP, ALP, CT; P>0.05).
Conclusion: The HPM-based intervention, through cognitive restructuring, behavioral modification, and environmental support, effectively enhanced thyroid function, ameliorated glucose-lipid metabolic disturbances, and mitigated chronic inflammation in patients with HT and DM.
Copyright (c) 2025 Miao Tang, Jiao Xu, Yanling Chen, Bo Zhou
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.